U.S. health spending began soaring in 1980

It’s been well documented the U.S. spends more per capita on healthcare than other high-income nations. A new analysis from the New York Times’ Upshot shows that that hasn’t always been the case.

Until 1980, the U.S. was similar to those other countries in per capita spending and life expectancy. Princeton University sociology professor Paul Starr, PhD, said high inflation and sluggish economic growth in the late 1970s hurt countries’ abilities to afford healthcare. The difference? "[O]ther countries have been able to put limits on healthcare prices and spending” while the U.S. relied on market forces.

As spending constraints eased, costly technological innovations began a “medical arms race” among hospitals and other providers, according to Brookings Institution health economist Henry Aaron, PhD. Some of these valuable but expensive treatments included coronary artery bypass grafting and drugs for HIV.

“Confronted with fiscal pressures, as the share of [gross domestic product] absorbed by healthcare spending began to get serious, other nations had mechanisms to hold down spending,” Aaron said. “We didn’t.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.